# US 2024/0002936 A1 · Use of brain organoids and single cell genomics to understand and treat neurodevelopmental and neuropsychiatric disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002936 A1
- Document ID: US20240002936A1
- Status: Published application
- Kind: A1
- Application number: 18/034,876
- Filed: 2021-11-01
- Published: 2024-01-04
- Earliest claimed: 2020-10-30
- Assignees: President and Fellows of Harvard College; The Broad Institute, Inc.; Massachusetts Institute of Technology
- Applicants: President and Fellows of Harvard College; The Broad Institute, Inc.; Massachusetts Institute of Technology
- Inventors: Paola Arlotta; Joshua Z. Levin; Amanda J. Kedaigle; Aviv Regev; Bruna Da Silveira Paulsen; Silvia Velasco; Martina Pigoni
- Web page: https://patentgrep.com/patent/US20240002936A1

## CPC

- C12N 5/0619: {Neurons}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/5088: {of vertebrates}
- C12N 2501/65: MicroRNA
- C12N 2513/00: 3D culture
- C12Q 2600/156: Polymorphic or mutational markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure is directed to methods of screening for pathological mechanisms in neurodevelopmental and neuropsychological disorders using brain organoids. The present disclosure is also directed to methods of screening agents using the brain organoids.

## Claims

### Claim 1

A method of screening for pathological mechanisms in neurodevelopmental disorders comprising
a. introducing one or more genetic variations to an organoid; and
b. profiling the mutant organoids using single-cell RNA sequencing, thereby identifying phenotypic alterations as a result of the genetic variation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the genetic variation causes haploinsufficiency in a gene.

### Claim 3 (depends on 2)

The method of claim 2, wherein the gene is selected from the group consisting of SUV420H1, PTEN, ARID1B and CHD8.

### Claim 4 (depends on 2)

The method of claim 2, wherein the gene is selected from the group consisting of SUV420H1, ARID1B and CHD8.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the neurodevelopmental disorder is autism spectrum disorder (ASD).

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the mutant organoids are screened one month after introduction of the genetic variation.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the mutant organoids are screened three months after introduction of the genetic variation.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the mutant organoids are screened six months after introduction of the genetic variation.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the mutant organoids are further profiled using immunohistochemistry.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the mutant organoids are further profiled using whole-proteome analysis.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the mutant organoids are further profiled using single cell Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the mutant organoids are further profiled using electrophysiological analysis.

### Claim 13 (depends on 1)

The method of claim 1, wherein the phenotypic alternation comprises asynchronous development of a cortical neuronal lineage.

### Claim 14 (depends on 1)

The method of claim 1, wherein the phenotypic alteration comprises asynchronous development of deep layer projection neuron lineage.

### Claim 15 (depends on 1)

The method of claim 1, wherein the phenotypic alteration comprises premature expansion of GABAergic neuron lineage.

### Claim 16

A method of screening a therapeutic agent, the method comprising:
a. contacting an organoid having one or more genetic variations with one or more candidate agents; and
b. testing effects of the one or more candidate agents on asynchronous development of a cortical neuronal lineage.

### Claim 17 (depends on 16)

The method of claim 16, wherein the asynchronous development of a cortical neuronal lineage comprises asynchronous development of deep layer projection neuron lineage.

### Claim 18 (depends on 16)

The method of claim 16, wherein the asynchronous development of a cortical neuronal lineage comprises premature expansion of GABAergic neuron lineage.

### Claim 19 (depends on 16)

The method of claim 16, wherein the genetic variation causes haploinsufficiency in a gene.

### Claim 20 (depends on 19)

The method of claim 19, wherein the gene is selected from the group consisting of SUV420H1, ARID1B and CHD8.
